Fluticasone furoate/levocabastine

Drug Profile

Fluticasone furoate/levocabastine

Alternative Names: FF/levocabastine; Levocabastine/FF; Levocabastine/fluticasone furoate

Latest Information Update: 05 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Androstadienes; Antiallergics; Antiasthmatics; Glucocorticoids; Piperidines; Sedating antihistamines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 04 May 2016 No development reported - Phase-I for Allergic rhinitis (In volunteers) in Australia (Intranasal)
  • 04 May 2016 No development reported - Phase-II for Allergic rhinitis in Austria (Intranasal)
  • 28 Feb 2014 GlaxoSmithKline completes a phase I trial in Healthy volunteers in Australia (NCT01962467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top